Peter M. Izmirly MD
Assistant Professor, Medicine, New York University School of Medicine
Join to View Full Profile
560 1st Ave# NyuNew York, NY 10016
Phone+1 212-263-0745
Dr. Izmirly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineFellowship, Rheumatology, 2004 - 2007- NYU Grossman School of MedicineResidency, Internal Medicine, 2001 - 2004
- New York University School of MedicineClass of 2001
Certifications & Licensure
NY State Medical License 2002 - 2026
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis.Lisa R Sammaritano, Anca Askanase, Bonnie L Bermas, Maria Dall'Era, Alí Duarte-García
Arthritis Care & Research. 2025-03-24 - 2 citationsExtrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network.Philip M Carlucci, Katherine Preisinger, Kristina K Deonaraine, Devyn Zaminski, Maria Dall'Era
Rheumatology. 2025-03-01 - Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials.Amit Saxena, Cristina Sorrento, Peter Izmirly, Janine Sullivan, Monica Gamez-Perez
Lupus Science & Medicine. 2025-01-06
Journal Articles
- A Prospective International Study on Adherence to Treatment in 305 Patients with Flaring SLE: Assessment by Drug Levels and Self‐Administered QuestionnairesPeter Izmirly, Michelle Petri, Meenakshi Jolly, Jill Buyon, Clinical Pharmacology & Therapeutics
Authored Content
- Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive MothersJuly 2020
- Tubulointerstitial Damage Predicts End Stage Renal Disease in Lupus Nephritis with Preserved to Moderately Impaired Renal Function: A Retrospective Cohort StudyFebruary 2018
Press Mentions
MCTD: Is It Just Letters?December 4th, 2024- Patients with Lupus Benefit from COVID-19 Vaccine Booster – ScienceDailyJuly 13th, 2022
- COVID-19 Booster Vaccine Beneficial for Lupus Patients: StudyJuly 13th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
